Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission

Standard

Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission : on behalf of the ALWP of the EBMT. / Shem-Tov, Noga; Peczynski, Christophe; Labopin, Myriam; Itälä-Remes, Maija; Blaise, Didier; Labussière-Wallet, Hélène; Socié, Gerard; Kröger, Nicolaus; Mielke, Stephan; Afanasyev, Boris; Chevallier, Patrice; Tischer, Johanna; Helbig, Grzegorz; Jindra, Pavel; Peric, Zinaida; Giebel, Sebastian; Mohty, Mohamad; Nagler, Arnon.

in: LEUKEMIA, Jahrgang 34, Nr. 1, 01.2020, S. 283-292.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

Shem-Tov, N, Peczynski, C, Labopin, M, Itälä-Remes, M, Blaise, D, Labussière-Wallet, H, Socié, G, Kröger, N, Mielke, S, Afanasyev, B, Chevallier, P, Tischer, J, Helbig, G, Jindra, P, Peric, Z, Giebel, S, Mohty, M & Nagler, A 2020, 'Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT', LEUKEMIA, Jg. 34, Nr. 1, S. 283-292. https://doi.org/10.1038/s41375-019-0544-3

APA

Shem-Tov, N., Peczynski, C., Labopin, M., Itälä-Remes, M., Blaise, D., Labussière-Wallet, H., ... Nagler, A. (2020). Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT. LEUKEMIA, 34(1), 283-292. https://doi.org/10.1038/s41375-019-0544-3

Vancouver

Bibtex

@article{df109118a1d94177b213dabaee95402a,
title = "Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT",
abstract = "Unmanipulated haploidentical allogeneic stem cell transplantation (Allo-SCT) has become an attractive alternative for patients lacking HLA-matched sibling or unrelated donors. However, data of outcome in ALL is still scarce. The outcomes of 1234 adult patients with ALL in first complete remission (CR1) who underwent Allo-SCT between 2007 and 2016 were analyzed. Comparison was done between haploidentical donor (Haplo) (136 patients), matched unrelated donor (MUD 10/10) (809 patients), and mismatched unrelated donor (MMUD 9/10) (289 patients). Univariate analysis showed similar outcomes in Haplo, MUD, and MMUD, including OS, LFS, RI, NRM, AGVHD, and CGVHD. In multivariate analysis, Haplo was not associated with worse outcomes compared to MUD 10/10 and MMUD 9/10. Indeed, compared to Haplo, the hazard ratio (HR) for LFS, OS, RI, NRM, AGVHD, and CGVHD were 1.1 (p = 0.7), 0.9 (p = 0.4), 1.35 (p = 0.2), 0.7 (p = 0.2), 1.1 (p = 0.8), and 0.8 (p = 0.2) for MUD, respectively, and 1.1 (p = 0.8), 1.0 (p = 1.0), 1.2 (p = 0.3), 0.8 (p = 0.4), 1.2 (p = 0.3), and 0.9 (p = 0.6) for MMUD, respectively. In conclusion, outcomes of adult patients with ALL in CR1 receiving Haplo Allo-SCT are comparable to MUD or MMUD transplants. Haplo should be considered as a clinically relevant option for patients lacking a matched sibling donor.",
author = "Noga Shem-Tov and Christophe Peczynski and Myriam Labopin and Maija It{\"a}l{\"a}-Remes and Didier Blaise and H{\'e}l{\`e}ne Labussi{\`e}re-Wallet and Gerard Soci{\'e} and Nicolaus Kr{\"o}ger and Stephan Mielke and Boris Afanasyev and Patrice Chevallier and Johanna Tischer and Grzegorz Helbig and Pavel Jindra and Zinaida Peric and Sebastian Giebel and Mohamad Mohty and Arnon Nagler",
year = "2020",
month = "1",
doi = "10.1038/s41375-019-0544-3",
language = "English",
volume = "34",
pages = "283--292",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission

T2 - on behalf of the ALWP of the EBMT

AU - Shem-Tov, Noga

AU - Peczynski, Christophe

AU - Labopin, Myriam

AU - Itälä-Remes, Maija

AU - Blaise, Didier

AU - Labussière-Wallet, Hélène

AU - Socié, Gerard

AU - Kröger, Nicolaus

AU - Mielke, Stephan

AU - Afanasyev, Boris

AU - Chevallier, Patrice

AU - Tischer, Johanna

AU - Helbig, Grzegorz

AU - Jindra, Pavel

AU - Peric, Zinaida

AU - Giebel, Sebastian

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2020/1

Y1 - 2020/1

N2 - Unmanipulated haploidentical allogeneic stem cell transplantation (Allo-SCT) has become an attractive alternative for patients lacking HLA-matched sibling or unrelated donors. However, data of outcome in ALL is still scarce. The outcomes of 1234 adult patients with ALL in first complete remission (CR1) who underwent Allo-SCT between 2007 and 2016 were analyzed. Comparison was done between haploidentical donor (Haplo) (136 patients), matched unrelated donor (MUD 10/10) (809 patients), and mismatched unrelated donor (MMUD 9/10) (289 patients). Univariate analysis showed similar outcomes in Haplo, MUD, and MMUD, including OS, LFS, RI, NRM, AGVHD, and CGVHD. In multivariate analysis, Haplo was not associated with worse outcomes compared to MUD 10/10 and MMUD 9/10. Indeed, compared to Haplo, the hazard ratio (HR) for LFS, OS, RI, NRM, AGVHD, and CGVHD were 1.1 (p = 0.7), 0.9 (p = 0.4), 1.35 (p = 0.2), 0.7 (p = 0.2), 1.1 (p = 0.8), and 0.8 (p = 0.2) for MUD, respectively, and 1.1 (p = 0.8), 1.0 (p = 1.0), 1.2 (p = 0.3), 0.8 (p = 0.4), 1.2 (p = 0.3), and 0.9 (p = 0.6) for MMUD, respectively. In conclusion, outcomes of adult patients with ALL in CR1 receiving Haplo Allo-SCT are comparable to MUD or MMUD transplants. Haplo should be considered as a clinically relevant option for patients lacking a matched sibling donor.

AB - Unmanipulated haploidentical allogeneic stem cell transplantation (Allo-SCT) has become an attractive alternative for patients lacking HLA-matched sibling or unrelated donors. However, data of outcome in ALL is still scarce. The outcomes of 1234 adult patients with ALL in first complete remission (CR1) who underwent Allo-SCT between 2007 and 2016 were analyzed. Comparison was done between haploidentical donor (Haplo) (136 patients), matched unrelated donor (MUD 10/10) (809 patients), and mismatched unrelated donor (MMUD 9/10) (289 patients). Univariate analysis showed similar outcomes in Haplo, MUD, and MMUD, including OS, LFS, RI, NRM, AGVHD, and CGVHD. In multivariate analysis, Haplo was not associated with worse outcomes compared to MUD 10/10 and MMUD 9/10. Indeed, compared to Haplo, the hazard ratio (HR) for LFS, OS, RI, NRM, AGVHD, and CGVHD were 1.1 (p = 0.7), 0.9 (p = 0.4), 1.35 (p = 0.2), 0.7 (p = 0.2), 1.1 (p = 0.8), and 0.8 (p = 0.2) for MUD, respectively, and 1.1 (p = 0.8), 1.0 (p = 1.0), 1.2 (p = 0.3), 0.8 (p = 0.4), 1.2 (p = 0.3), and 0.9 (p = 0.6) for MMUD, respectively. In conclusion, outcomes of adult patients with ALL in CR1 receiving Haplo Allo-SCT are comparable to MUD or MMUD transplants. Haplo should be considered as a clinically relevant option for patients lacking a matched sibling donor.

U2 - 10.1038/s41375-019-0544-3

DO - 10.1038/s41375-019-0544-3

M3 - SCORING: Journal articles

C2 - 31427719

VL - 34

SP - 283

EP - 292

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 1

ER -